Lineage Cell Therapeutics Q2 Earnings Call Highlights

Impact · against what's priced in

Lineage Cell Therapeutics (LCTX) sees a potential valuation lift from its AlloSCOPE platform's ability to drive COGS down to hundreds of dollars per dose and the external funding of its hearing loss program. While progress in the corneal and spinal cord injury programs is positive, the manufacturing scalability is the primary driver for long-term commercial viability.

LCTX+0.60

No priced-in read yet

In context

The AlloSCOPE platform's potential to reduce cell-therapy production costs to hundreds of dollars per dose and the $12 million funding from William Demant Invest for the ReSonance program provide concrete catalysts for scalability and risk reduction.

• earnings▲10%
• biotech
• LCTX
• RHHBY
• allogeneic
• cell therapy
• corneal disease
• diabetes
• fda
• hearing loss